These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 36119088)

  • 1. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.
    Gehlert CL; Rahmati P; Boje AS; Winterberg D; Krohn S; Theocharis T; Cappuzzello E; Lux A; Nimmerjahn F; Ludwig RJ; Lustig M; Rösner T; Valerius T; Schewe DM; Kellner C; Klausz K; Peipp M
    Front Immunol; 2022; 13():957874. PubMed ID: 36119088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering.
    Roßkopf S; Eichholz KM; Winterberg D; Diemer KJ; Lutz S; Münnich IA; Klausz K; Rösner T; Valerius T; Schewe DM; Humpe A; Gramatzki M; Peipp M; Kellner C
    Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33212776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.
    Kellner C; Derer S; Valerius T; Peipp M
    Methods; 2014 Jan; 65(1):105-13. PubMed ID: 23851282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.
    Kellner C; Otte A; Cappuzzello E; Klausz K; Peipp M
    Transfus Med Hemother; 2017 Sep; 44(5):327-336. PubMed ID: 29070978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
    Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
    Front Immunol; 2021; 12():715719. PubMed ID: 34413859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering IgG1 Fc Domains That Activate the Complement System.
    Lee CH; Delidakis G
    Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.
    Wirt T; Rosskopf S; Rösner T; Eichholz KM; Kahrs A; Lutz S; Kretschmer A; Valerius T; Klausz K; Otte A; Gramatzki M; Peipp M; Kellner C
    Transfus Med Hemother; 2017 Sep; 44(5):292-300. PubMed ID: 29070974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.
    Moore GL; Chen H; Karki S; Lazar GA
    MAbs; 2010; 2(2):181-9. PubMed ID: 20150767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.
    van Erp EA; Luytjes W; Ferwerda G; van Kasteren PB
    Front Immunol; 2019; 10():548. PubMed ID: 30967872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
    Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
    Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of amino acid substitutions on the biological activity of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
    Aoyama M; Tada M; Tatematsu KI; Hashii N; Sezutsu H; Ishii-Watabe A
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2633-2638. PubMed ID: 30119885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
    Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
    Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
    Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
    Front Immunol; 2019; 10():562. PubMed ID: 30984171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.
    Chung AW; Crispin M; Pritchard L; Robinson H; Gorny MK; Yu X; Bailey-Kellogg C; Ackerman ME; Scanlan C; Zolla-Pazner S; Alter G
    AIDS; 2014 Nov; 28(17):2523-30. PubMed ID: 25160934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
    Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC
    Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.